[go: up one dir, main page]

ATE360633T1 - N-substituierte hydromorphone und ihre anwendung - Google Patents

N-substituierte hydromorphone und ihre anwendung

Info

Publication number
ATE360633T1
ATE360633T1 AT03754837T AT03754837T ATE360633T1 AT E360633 T1 ATE360633 T1 AT E360633T1 AT 03754837 T AT03754837 T AT 03754837T AT 03754837 T AT03754837 T AT 03754837T AT E360633 T1 ATE360633 T1 AT E360633T1
Authority
AT
Austria
Prior art keywords
application
hydromorphones
substituted
formula
substituted hydromorphones
Prior art date
Application number
AT03754837T
Other languages
English (en)
Inventor
Donald J Kyle
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE360633T1 publication Critical patent/ATE360633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03754837T 2002-09-25 2003-09-24 N-substituierte hydromorphone und ihre anwendung ATE360633T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41325402P 2002-09-25 2002-09-25

Publications (1)

Publication Number Publication Date
ATE360633T1 true ATE360633T1 (de) 2007-05-15

Family

ID=32043224

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754837T ATE360633T1 (de) 2002-09-25 2003-09-24 N-substituierte hydromorphone und ihre anwendung

Country Status (18)

Country Link
US (1) US6825205B2 (de)
EP (2) EP1803724A1 (de)
JP (2) JP4806190B2 (de)
KR (1) KR20050074462A (de)
CN (1) CN100387600C (de)
AT (1) ATE360633T1 (de)
AU (1) AU2003272642B2 (de)
BR (1) BR0314488A (de)
CA (1) CA2500118C (de)
CY (1) CY1106697T1 (de)
DE (1) DE60313478T2 (de)
DK (1) DK1543010T3 (de)
ES (1) ES2286461T3 (de)
MX (1) MXPA05003104A (de)
NZ (1) NZ538726A (de)
PT (1) PT1543010E (de)
WO (1) WO2004029059A1 (de)
ZA (1) ZA200502174B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
RU2009112685A (ru) 2006-09-20 2010-10-27 Маллинкродт Инк. (Us) Получение замещенных морфинан-6-онов и их солей и промежуточных соединений
MX2009005455A (es) * 2006-11-22 2009-08-28 Progenics Pharm Inc (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MX2009005461A (es) * 2006-11-22 2009-08-28 Progenics Pharm Inc N-oxidos de analogos de 4,5-epoxi-morfinano.
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
EP2137189B1 (de) * 2007-03-06 2015-05-06 Mallinckrodt LLC Verfahren zur herstellung quaternärer n-alkyl-morphinin-alkaloid-derivate
JP5581211B2 (ja) * 2007-08-09 2014-08-27 レンセラール ポリテクニック インスティチュート 第四級オピオイドカルボキサミド
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
US20110112129A2 (en) * 2007-11-26 2011-05-12 Pharmacofore, Inc. Peripheral Phenolic Opioid Antagonist
WO2009146288A1 (en) 2008-05-27 2009-12-03 Mallinckrodt Inc. Processes and compounds for the preparation of normorphinans
WO2010028004A2 (en) 2008-09-03 2010-03-11 Mallinckrodt Inc. Substituted berbines and processes for their synthesis
JP5977240B2 (ja) 2010-09-21 2016-08-24 パーデュー、ファーマ、リミテッド、パートナーシップ ブプレノルフィン類似体
TW201431842A (zh) 2012-11-09 2014-08-16 Purdue Pharma Lp 苯並嗎啡烷類似物及其應用
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
EP3087078B1 (de) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl-analoga von orvinolen
EP3087079B1 (de) 2013-12-26 2019-04-03 Purdue Pharma LP Opioidrezeptormodulierende oxabicyclo[2.2.2]oktanmorphinane
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
CN106414408A (zh) 2013-12-26 2017-02-15 普渡制药公司 缩合环吗啡喃和其用途
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015183780A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
JP6360915B2 (ja) 2014-06-13 2018-07-18 パーデュー、ファーマ、リミテッド、パートナーシップ アザモルフィナン誘導体及びその使用
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
CN117567477A (zh) * 2023-11-15 2024-02-20 宜昌人福药业有限责任公司 一种氢吗啡酮和二氢吗啡类药物低分子聚乙二醇化物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ES2051742T3 (es) * 1987-09-10 1994-07-01 Univ Chicago Derivados cuaternarios de noroxi-morfina que mitigan las nauseas y la emesis.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1998023290A1 (en) * 1996-11-25 1998-06-04 Toray Industries, Inc. Antipruritic agent
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan

Also Published As

Publication number Publication date
JP2006503850A (ja) 2006-02-02
CY1106697T1 (el) 2012-05-23
ZA200502174B (en) 2006-05-31
CA2500118C (en) 2011-04-12
CN100387600C (zh) 2008-05-14
JP2011042681A (ja) 2011-03-03
HK1080456A1 (en) 2006-04-28
JP4806190B2 (ja) 2011-11-02
ES2286461T3 (es) 2007-12-01
US20040067973A1 (en) 2004-04-08
CA2500118A1 (en) 2004-04-08
KR20050074462A (ko) 2005-07-18
EP1803724A1 (de) 2007-07-04
DE60313478T2 (de) 2008-01-03
US6825205B2 (en) 2004-11-30
DK1543010T3 (da) 2007-09-17
EP1543010B1 (de) 2007-04-25
AU2003272642A1 (en) 2004-04-19
DE60313478D1 (de) 2007-06-06
MXPA05003104A (es) 2005-05-27
PT1543010E (pt) 2007-07-26
NZ538726A (en) 2006-11-30
EP1543010A1 (de) 2005-06-22
CN1684967A (zh) 2005-10-19
BR0314488A (pt) 2005-08-02
AU2003272642B2 (en) 2009-07-09
WO2004029059A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE360633T1 (de) N-substituierte hydromorphone und ihre anwendung
BR0312934A (pt) Derivados de 8-hidróxi quinolina
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
IL197642A (en) Heterocyclic Derivatives and Their Uses to Prepare Pharmaceutical Preparations for the Treatment of Opioid Receptor Syndromes
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
WO2002085853A3 (en) Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
ATE414516T1 (de) Morphinanderivate als mittel gegen juckreiz
SE9902267D0 (sv) New compounds
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
BR0206687A (pt) Método para prevenir e tratar dores viscerais e distúrbios gastrointestinais
SI1362590T1 (sl) Uporaba ciklobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje
MXPA05013233A (es) Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
NO20033634L (no) GLyT-1-inhibitorer
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
SI1553938T1 (sl) Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
WO2007053353A3 (en) Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1543010

Country of ref document: EP